Endonovo Therapeutics’ (OTCQB: ENDV) proprietary SofPulse(R) flagship device recently received a glowing review for minimizing pain from a foot-and-ankle specialist in Ohio who underwent tendon surgery. An article discussing the company reads, “In a homemade video, Dr. Jane Graenber, DPM, of the Foot and Ankle Wellness Center in Delaware, Ohio, attests that Endonovo’s SofPulse(R) electroceutical device has helped her to remain generally pain free a day after the tendon surgery, such that she says she has only used three doses of Tylenol for relief (no prescription pain pills) during the interim since her procedure (http://nnw.fm/KgYZ6). . . ‘This device is putting out a micro-current to my surgical area every two hours. . . . And it’s taken care of the pain, and I’m sitting here very comfortably,’ Graenber states in the video. ‘At our practice, we may be starting to include this postoperatively as an option to reduce pain. This was a pretty big surgery, and I’m really very comfortable. So I’m giving credit to a good surgeon but also a new device that may revolutionize pain (treatment) after surgery.’”
To view the full article, visit http://nnw.fm/2Vqyf
About Endonovo Therapeutics
Endonovo Therapeutics is a commercial-stage developer of noninvasive, wearable Electroceuticals(R) therapeutic devices. The company’s current portfolio of commercial and clinical-stage wearable Electroceuticals(R) therapeutic devices addresses wound healing, pain, postsurgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (“CNS”) disorders including traumatic brain injury (“TBI”), acute concussions, post concussion syndrome and multiple sclerosis. The company’s noninvasive Electroceutical(R) therapeutic device, SofPulse(R), which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA cleared and CE marked for the palliative treatment of soft-tissue injuries and postoperative pain and edema and has CMS national coverage for the treatment of chronic wounds. The company’s current portfolio of preclinical-stage Electroceuticals(R) therapeutic devices addresses chronic kidney disease, liver-disease nonalcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The company’s noninvasive, wearable Electroceuticals(R) therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth-factor cascades necessary for healing to occur. For more information, visit the company’s website at www.Endonovo.com.
NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://nnw.fm/ENDV
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]